الفهرس Only 14 pages are availabe for public view
 |  | from | 144 |  |  |
| | | from | 144 | | |
Abstract
Erythropoietin (EPO) is an endogenous glycoprotein (35 kDa) that is synthesized by the interstitial cells in the kidney (Pertibular fibroblast of renal cortex) and locally by some other tissues, including the brain, in response to tissue hypoxia or red cell mass decrease. It stimulates erythrocyte production from the blood marrow. This protein is of 165 amino acids four of which are actually is available in a recombinant form. This treatment is relatively expensive in many developing countries so it has not been available to all patients who need it .Therefore a less expensive forms of these drugs are developed. In 1990 several pharmaceutical companies started in developing what was termed {u2018}biosimilars{u2019}. The current study focus on assess the efficacy of biosimilar alpha rHuEPO versus innovator product after administration subcutaneously for the treatment of anemia in patients with CRF and on evaluate the similarities and differences in physicochemical properties between biosimilars recombinant human erythropoietin (rHuEPO) purchased from different manufactures with the Innovator product. In conclusion, the quality of biosimilar-C is high as innovator product (Eprex) in quality and it is safe in clinical practice, effective and stable as innovator product